Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-12-19 00:00:00 ET · period of report 2023-12-17 · accession 0001610717-23-000409 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-19 | 2023-12-17 | CTMX | ROWLAND LLOYD A | GC | M - OptEx | $0.00 | +11.2K | 102.1K | +12% | $0 |
| D | 2023-12-19 | 2023-12-17 | CTMX | ROWLAND LLOYD A | GC | M - OptEx | $0.00 | -11.2K | 11.2K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-17 | M | A | 11,250 | $0.00 | 102,073 | D | — | — | (F2) Includes 41,875 restricted stock units. (F3) Includes 4,560 shares and 5,654 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively. |
| 2 | Derivative | Performance Stock Units (PSUs) | 2023-12-17 | M | D | 11,250 | $0.00 | 11,250 | D | — · — to — | 11,250 Common Stock | (F1) Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. (F4) Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024. |